Eli Lilly Strengthens Market Lead with Superior Trial Results for Oral GLP-1 Drug

Eli Lilly's oral drug orforglipron showed superior blood sugar and weight loss results vs. Novo's oral semaglutide in a landmark Phase 3 study, boosting its competitive position.

A landmark clinical study has delivered a significant competitive win for Eli Lilly in the high-stakes market for diabetes and weight-loss medications. Newly published data reveals the company's experimental oral drug, orforglipron, demonstrated clear superiority over a rival pill from Novo Nordisk across all primary efficacy measures.

Head-to-Head Trial Shows Clear Efficacy Advantage

The findings, released in The Lancet on Thursday, stem from the ACHIEVE-3 study—the first Phase 3 trial to directly compare two oral GLP-1 therapies. Over 52 weeks, researchers evaluated four treatment arms involving a total of 1,698 participants.

The results were decisive. A 36 mg dose of Eli Lilly's orforglipron reduced long-term blood sugar levels (A1C) by 2.2 percentage points. This performance notably surpassed the 1.4 percentage point reduction achieved by a 14 mg dose of Novo Nordisk's oral semaglutide. The weight loss data was even more striking: patients on orforglipron lost an average of 8.9 kilograms, which is 73.6% more than the 5.0 kilograms lost by those on the competing therapy.

Furthermore, 85.4% of patients taking orforglipron 36 mg achieved an A1C level below 7%, the standard treatment goal for well-managed diabetes. This compares favorably to the 66.1% rate seen with oral semaglutide. Orforglipron also offers a practical dosing advantage, as it can be taken at any time without regard to meals or water intake restrictions, unlike some other oral treatments.

Safety Profile and Regulatory Pathway

The detailed safety data presented a more nuanced picture. Mild to moderate gastrointestinal side effects, including nausea, diarrhea, and vomiting, were reported by approximately 58% of patients in the orforglipron 36 mg group, compared to 45% for those on oral semaglutide. Discontinuation rates due to adverse events were also higher for Eli Lilly's drug, at 9.7% versus 4.9%.

How regulatory agencies and prescribing physicians weigh this efficacy-safety balance will be crucial for the drug's commercial potential. Eli Lilly has already submitted orforglipron for approval in more than 40 countries. A U.S. Food and Drug Administration (FDA) decision for its obesity indication is anticipated in the second quarter of 2026.

Building Momentum in a Competitive Landscape

The positive ACHIEVE-3 data is the latest in a series of strategic advances for the U.S. pharmaceutical giant. Just on February 23, Novo Nordisk's next-generation obesity injection, CagriSema, failed to outperform Eli Lilly's Zepbound in a direct comparison. On that same day, Eli Lilly launched a new monthly dosage format for Zepbound. Market analyses now indicate the company controls approximately 60% of the U.S. market for GLP-1 medications.

Eli Lilly is also expanding its pipeline beyond the GLP-1 category. On February 9, the firm announced the acquisition of Orna Therapeutics for up to $2.4 billion, gaining access to a circular RNA platform and a clinically mature in vivo CAR-T candidate targeting autoimmune diseases like lupus.

Financial Performance and Upcoming Catalysts

The company's operational strength was underscored by its fourth-quarter 2025 results. Revenue surged 43% to $19.3 billion, propelled by strong sales of Mounjaro and Zepbound. Adjusted earnings per share rose 42% to $7.54, exceeding the analyst consensus estimate of $6.67. For 2026, Eli Lilly provided a revenue forecast between $80 and $83 billion, well above the then-prevailing consensus estimate of $77.62 billion.

The coming months are set to be eventful. Results from three additional ACHIEVE studies are expected throughout the year, and a potential FDA approval for another indication is on the horizon for early spring. This continued product offensive appears to be consolidating Eli Lilly's lead, while its main competitor, Novo Nordisk, finds itself increasingly on the defensive.